Publications
Find coverage of the latest original articles on Lupus, focusing on those with data on therapeutic interventions and those that have clinical impact.
October 2025
EULAR recommendations for the management of systemic lupus erythematosus with kidney involvement: 2025 update
Ann Rheum Dis 2025;0:1−16 Doi: 10.1016/j.ard.2025.09.007
The updated EULAR recommendations provide evidence- and expert-based consensus on the management of SLE with kidney involvement, adjusted for severity, and taking into consideration long-term efficacy, safety, cost, and local availability of drugs. Fanouriakis A et al. updated the 2019 EULAR/ ERA-EDTA recommendations for the management of SLE with kidney involvement, taking into consideration emerging evidence and recent developments in the field.
September 2025
EULAR recommendations for a core dataset to support clinical care and translational and observational research in systemic lupus erythematosus
Ann Rheum Dis 2025:0;1−11 Doi: 10.1016/j.ard.2025.07.001
The presented clinical core dataset and its research extension are designed to improve SLE patient care and facilitate collaborative research by ensuring the comparability of datasets and cohort descriptions. The aim of this EULAR taskforce by Mucke et al. was to define a core set of essential items for the comprehensive care of SLE patients in clinical practice, with an extension for vital elements required for translational and observational research.
November 2023
EULAR Recommendations for the Management of Systemic Lupus Erythematosus: 2023 Update
Ann Rheum Dis 2023;83(1):15–29 DOI: 10.1136/ard-2023-224762
The objective of this international task force was to update the EULAR recommendations for the management of SLE. The Task Force agreed on 5 overarching principles and 13 recommendations, generating an overall framework for the approach to a patient with SLE. The updated recommendations provide consensus guidance on the management of SLE, combining evidence and expert opinion.
Keywords:
March 2022
EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome
Ann Rheum Dis. 2022. Epub ahead of print doi: 10.1136/annrheumdis-2021-221733
EULAR recommendations can guide clinical practice and future research for improving cardiovascular risk (CVR) management in rheumatic and musculoskeletal diseases.